Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKRP) Amortization of Deferred Charges (2010 - 2012)

Bruker posted quarterly Amortization of Deferred Charges of $200000.0 for Q3 2012, up 100.0% year-on-year from $100000.0 in Q4 2011, and up 100.0% on a QoQ basis from $100000.0 in Q2 2012.

Bruker (BRKRP) has 3 years of Amortization of Deferred Charges data on file, last reported at $200000.0 in Q3 2012.

  • For the quarter ending Q3 2012, Amortization of Deferred Charges rose 100.0% year-over-year to $200000.0; the trailing twelve-month figure through Sep 2012 stood at $700000.0 (up 40.0% YoY), and the FY2011 full-year result was $600000.0, changed 0.0% from the prior year.
  • Amortization of Deferred Charges for Q3 2012 stood at $200000.0, up from $100000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $200000.0 in Q1 2010 and bottomed at $100000.0 in Q2 2010.
  • The 3-year median for Amortization of Deferred Charges is $200000.0 (2010), against an average of $154545.5.
  • Peak annual rise in Amortization of Deferred Charges reached 100.0% in 2011, while the deepest fall reached 50.0% in 2011.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $100000.0 in 2010, then soared by 100.0% to $200000.0 in 2011, then changed by 0.0% to $200000.0 in 2012.
  • The last three Amortization of Deferred Charges figures came in at $200000.0 (Q3 2012), $100000.0 (Q2 2012), and $200000.0 (Q1 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Bruker - - 379.80 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2012 200,000.00
Sep 30, 2012 200,000.00
Jun 30, 2012 100,000.00
Jun 30, 2012 100,000.00
Mar 31, 2012 200,000.00
Mar 31, 2012 200,000.00
Dec 31, 2011 200,000.00
Dec 31, 2011 200,000.00
Sep 30, 2011 100,000.00
Sep 30, 2011 100,000.00
Jun 30, 2011 200,000.00
Jun 30, 2011 200,000.00
Mar 31, 2011 100,000.00
Mar 31, 2011 100,000.00
Dec 31, 2010 100,000.00
Dec 31, 2010 100,000.00
Sep 30, 2010 200,000.00
Sep 30, 2010 200,000.00
Jun 30, 2010 100,000.00
Jun 30, 2010 100,000.00
Mar 31, 2010 200,000.00
Mar 31, 2010 200,000.00